AstraZeneca acquired preclinical biotech Omniose, adding a bioconjugation platform for conjugate vaccines against serious bacterial infections.
|Articles|May 1, 2020
- BioPharm International-05-01-2020
- Volume 33
- Issue 5
Pre-Packed Columns
Tosoh Bioscience introduced the SkillPak 1 mL and 5 mL pre-packed columns for fast method development and resin screening of monoclonal antibodies, antibody constructs, oligonucleotides, proteins, and viruses.
Advertisement
Tosoh Bioscience introduced the SkillPak 1 mL and 5 mL pre-packed columns for fast method development and resin screening of monoclonal antibodies, antibody constructs, oligonucleotides, proteins, and viruses.
The columns come pre-packed with Toyopearl, TSKgel, or Ca++Pure-HA process chromatography media and are ready for use immediately. Additionally, the high performance, scalable columns are available with short delivery times in affinity, anion and cation exchange, hydrophobic interaction, and size exclusion chromatographic modes. Peak performance is guaranteed, according to the company, and the columns can be operated directly with low- or medium-pressure liquid chromatography systems.
Articles in this issue
over 5 years ago
Considerations for Closures in Cold Storageover 6 years ago
Fluid Handling Considerationsover 6 years ago
How Fast Is Too Fast?over 6 years ago
Building Better Bioassaysover 6 years ago
Modern Drug Manufacturing Key to COVID-19 Responseover 6 years ago
Starting a Career in the Bio/Pharmaceutical Industryover 6 years ago
Good Automation Practices for Remote Operationsover 6 years ago
Mass Flow ControllersAdvertisement
Related to this article
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Merck's GLP-1/glucagon co-agonist raised MASH resolution versus placebo at 52 weeks, but fibrosis and dose-response questions remain.
Larimar Therapeutics has completed its rolling BLA for nomlabofusp, a frataxin replacement fusion protein, seeking accelerated approval based on skin frataxin as a novel surrogate endpoint. The company expects a potential US approval in mid-2027.
FDA granted RMAT and Fast Track designations to AbelZeta’s anti-CD20/CD19 CAR-T therapy prizlon-cel for relapsed or refractory large B-cell lymphoma. The company plans US studies after prior CAR-T therapy and in the second-line setting.
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
More monoclonal antibodies are moving from IV infusion to subcutaneous injection, but dose, volume, and viscosity still limit the switch. This FAQ covers the formulation science, the enabling technologies, what regulators require, and what remains unresolved.
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
3
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
4
FDA Grants RMAT and Fast Track Designations to AbelZeta’s Bispecific CAR-T Prizlon-cel in Large B-Cell Lymphoma
5